Novo Nordisk presents new Phase III data for next gen amylin cagrilintide The Pharmaletter A new drug combo of semaglutide (GLP 1 receptor agonist) with cagrilintide (amylin analogue) failed to do as well as tirzepatide (GLP 1 GIP receptor agonist). The future of these medicines is hitting different receptors. Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Novo Nordisk's CagriSema Falls Short in Head to Head Trial vs Zepbound Bryce Platt, PharmD posted on the topic LinkedIn Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace TrimRX Novo Nordisk submits application for FDA approval of CagriSema for weight management